US4853218A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Zinc-protamine-alpha interferon complex
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1987-02-24
•
Granted: 1989-08-01
•
Expires: 2007-02-24
Abstract
Abstract An insoluble zinc-protamine alpha interferon complex useful as an injectable sustained release dosage form for administering alpha interferon is disclosed.
Inventors
- 👤 Zachary Yim
- 👤 Michael A. Zupon
- 👤 Imtiaz A. Chaudry
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 08:31
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/212; A61K33/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
28 words
A sustained release pharmaceutical composition comprising a parenterally acceptable insoluble zinc-protamine-alpha interferon complex, wherein the alpha interferon is present at 2×10 6 to 200×10 6 International Units/ml complex.
Claim 2
Dependent Claim
28 words
A sustained release pharmaceutical composition comprising a parenterally acceptable insoluble zinc-protamine-alpha interferon complex, wherein the alpha interferon is present at 2×10 6 to 200×10 6 International Units/ml complex.
Claim 3
Dependent Claim
97 words
A composition of claim 1 comprising 2×10 6 to 200×10 6 International Units of alpha interferon, 1 to 20 mg of a zinc salt, 0.25 to 5 mg of protamine free base or a protamine salt, 0 to 50 mg glycine and 0 to 10 mg human serum albumin per ml of a compatible buffer at pH 7.5 to 8.5, wherein the zinc salt is selected from the group consisting of zinc acetate, zinc chloride and zinc sulfate and wherein the protamine salt is selected from the group consisting of protamine sulfate, protamine chloride and protamine phosphate.
Claim 4
Dependent Claim
8 words
A composition of claim 2 comprising zinc acetate.
Claim 5
Dependent Claim
8 words
A composition of claim 2 comprising protamine sulfate.
Claim 6
Dependent Claim
10 words
A composition of claim 2 at pH 8.0 to 8.4.
Claim 7
Dependent Claim
38 words
A composition of claim 2 comprising 4.0 mg zinc acetate, 2.5 mg protamine sulfate, 0.6 mg sodium hydroxide, 1 mg human serum albumin and 20 mg glycine per ml of solution, wherein the buffer is a phosphate buffer.
Claim 8
Dependent Claim
16 words
A composition of claim 6 comprising 2 x 10 7 International Units of alpha 2 interferon.
Claim 9
Dependent Claim
8 words
A composition of claim 6 at pH 8.2.
Claim 10
Dependent Claim
8 words
A composition of claim 7 at pH 8.2.
Claim 11
Dependent Claim
31 words
A method of treating basal cell carcinoma comprising administering an amount of a composition of claim 1 effective to treat basal cell carcinoma to a mammal in need of such treatment.
References Cited (Backward Citations)
US3912807A
Cited
US4289690A
Cited
EP0032134A2
Cited
EP0051873A2
Cited
US4496537A
Cited
US4605555A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-31 | 1993-01-30 | 1993-08-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-31 | 1997-01-30 | 1997-08-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-31 | 2001-01-30 | 2001-08-01 | $7700.00 | Window Closed / Lapsed |